中国当代儿科杂志2026，Vol.28Issue(4)：417-422,6.DOI:10.7499/j.issn.1008-8830.2508146
贝林妥欧单抗联合达沙替尼治疗儿童费城染色体阳性急性淋巴细胞白血病的安全性分析
Safety of blinatumomab combined with dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia
郑方圆 1丁明明 1陆爱东 1贾月萍 1曾慧敏 1张乐萍1
作者信息
- 1. 北京大学人民医院儿科,北京 100044
- 折叠
摘要
Abstract
Objective To evaluate the safety of blinatumomab combined with dasatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL).Methods A retrospective review was conducted of clinical data for children with Ph+ALL treated with blinatumomab plus dasatinib in the Department of Pediatrics,Peking University People's Hospital,from August 2023 to June 2025.Adverse events during therapy were recorded to assess safety.Results Ten children were included(7 boys,3 girls),with a total of 13 instances of combination therapy.After treatment,B C R::A B L 1 transcript levels decreased from baseline or remained persistently negative.At a median follow-up of 13 months,all patients were alive without disease relapse.During treatment,dasatinib trough and peak plasma concentrations were not significantly affected(P>0.05).Major adverse events were as follows:hematologic toxicity(grade Ⅰ-Ⅱ:77％;grade Ⅲ-Ⅳ:23％;median time to onset:4 days;median duration:7 days),cytokine release syndrome(all grade I;incidence:61％;median time to onset:3 days;duration:2 days),neurotoxicity(grade Ⅰ-Ⅱ:30％;grade Ⅲ-Ⅳ:7％;median time to onset:3 days;duration:1 day),and hypogammaglobulinemia(incidence:90％;median time to onset:13 days),with six patients requiring long-term intravenous immunoglobulin therapy.All adverse events resolved with supportive care,and no treatment-related deaths occurred.Conclusions Blinatumomab combined with dasatinib is well tolerated in pediatric Ph+ALL,and the adverse events are manageable.关键词
贝林妥欧单抗/达沙替尼/急性淋巴细胞白血病/费城染色体阳性/儿童Key words
Blinatumomab/Dasatinib/Acute lymphoblastic leukemia/Philadelphia chromosome-positive/Child引用本文复制引用
郑方圆,丁明明,陆爱东,贾月萍,曾慧敏,张乐萍..贝林妥欧单抗联合达沙替尼治疗儿童费城染色体阳性急性淋巴细胞白血病的安全性分析[J].中国当代儿科杂志,2026,28(4):417-422,6.
